Latest Breaking News On - தீர்ப்பியல்ட் மேலாண்மை - Page 24 : comparemela.com

m ET ENGLEWOOD, Colo. and GRAND PRAIRIE, Texas, Dec. 10, 2020 (GLOBE NEWSWIRE) Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, and Neos Therapeutics, Inc. (NASDAQ:NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today announced that they have entered into a definitive merger agreement pursuant to which Neos will merge with a wholly owned subsidiary of Aytu in an all-stock transaction. Transaction Details Upon the effectiveness of the merger (the Merger ), Neos stockholders will be entitled to receive 0.1088 shares of common stock of Aytu for each share of Neos common stock held, after taking into account the one-for-ten reverse split of Aytu s common stock that was effected on December 8, 2020. The transaction will result in Neos stockholders owning approximately 30% of the fully diluted common shares o

United statesGrand prairieBeth hechtNeos rxconnectJerry mclaughlinJosh disbrowAytu bioscienceInnovus pharmaceuticals incHealth partnersNeos therapeutics incDorsey whitneyNeutron merger sub incExchange commissionAytu bioscience incSecurities exchangeGoodwin procter